Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Rotigotine Transdermal Delivery in PD and RLS
2026-09-16
The reference review explains how Rotigotine was developed as a continuously delivered dopamine D2/D3 receptor agonist for Parkinson’s disease and restless legs syndrome. Its central contribution is linking pharmacology, transdermal formulation, pharmacokinetics, and randomized clinical evidence to the rationale for sustained dopaminergic receptor stimulation.
-
Pentoxifylline: From cAMP Signal to Assay Insight
2026-09-16
Pentoxifylline is a phosphodiesterase inhibitor whose cAMP-dependent effects can reshape inflammatory assay interpretation. This guide connects molecular signaling, age-specific monocyte biology, and practical readout selection to improve mechanistic research decisions.
-
IgSF6, ER Stress, and Antibacterial Macrophage Defense
2026-09-15
The reference study identifies ER-localized IgSF6 as a regulator of intestinal macrophage stress responses rather than simply a conventional cell-surface immune molecule. Loss of Igsf6 improved resistance to Salmonella infection through IRE1α–XBP1 signaling and reactive oxygen species, but increased susceptibility to DSS-induced colitis, revealing a context-dependent trade-off between antibacterial defense and intestinal homeostasis.
-
Cyclophilin A and Cyclosporine Resistance in Mice
2026-09-15
The reference study established that cyclophilin A is the principal intracellular mediator of cyclosporine-driven immunosuppression, despite the presence of multiple related cyclophilins. By combining Ppia gene deficiency with cellular, allogeneic, and adoptive-reconstitution experiments, the authors connected drug resistance to impaired calcineurin inhibition and provided a rigorous framework for interpreting ligand-dependent immune suppression.
-
TH287 Radiosensitizes CRPC Cells to Radiation
2026-09-14
A 2026 study found that the MTH1 inhibitor TH287 increased ionizing-radiation sensitivity in PC-3 and DU-145 castration-resistant prostate cancer cells. The strongest combination effect occurred when irradiation followed TH287 exposure by 12 hours, linking treatment sequence with apoptosis and cell-cycle disruption.
-
Clozapine Workflows for Schizophrenia Research
2026-09-14
Clozapine offers a practical pharmacological benchmark for receptor profiling, ERK1/2 pathway assays, and dose-sensitive neurotoxicity studies. Used alongside targeted magnetic stimulation, it helps separate broad drug-mediated signaling from region-specific circuit modulation in preclinical schizophrenia research.
-
Concanavalin A Targets Conserved Coronavirus N-Glycans
2026-09-13
Guo and colleagues identify conserved high-mannose N-linked glycans near the coronavirus spike S2′ cleavage site as a broad antiviral vulnerability. Using fusion, pseudovirus, authentic-virus, biochemical, and animal models, the study shows that concanavalin A blocks spike activation and reduces hCoV-NL63 disease in vivo, while also defining important limitations for translation.
-
Optimizing Functional Platelets from hiPSCs
2026-09-12
A 2026 study developed an optimized embryoid-body protocol for generating megakaryocytes and functional platelets from human induced pluripotent stem cells. By increasing starting cell input, using human platelet lysate and replacing selected cytokines with small molecules, the workflow shortened differentiation to 19 days, produced 14.9 platelets per iPSC, and reduced reported costs by 58.3%.
-
JAK Inhibitors: Endothelial Vascular Effects
2026-09-11
A 2025 comparative study shows that approved JAK inhibitors consistently suppress inflammatory IL-6 release in cytokine-stimulated endothelial cells, but differ substantially in their effects on adhesion molecules, coagulation factors, and apoptosis. The findings caution that anti-inflammatory activity does not necessarily indicate endothelial protection and provide a framework for interpreting tofacitinib responses in vascular and immune assays.
-
HOXC8, Caspase-1, and Pyroptosis in Lung Cancer
2026-09-11
The reference study identifies HOXC8 as a transcriptional suppressor of CASP1 that protects non-small cell lung carcinoma cells from ASC-independent pyroptosis. Its mechanistic model connects HOXC8–HDAC1/2 recruitment at the CASP1 promoter with tumor maintenance and shows that cholesterol-conjugated HOXC8 siRNA can slow NSCLC tumorigenesis.
-
Cell Lysis Buffer for WB and IP in CAF Studies
2026-09-10
Cell lysis buffer for WB and IP can determine whether signaling proteins, phosphorylation states, and protein interactions remain measurable in tumor-microenvironment studies. This guide connects K1123 reagent chemistry with the ANGPTL4-IQGAP1 mechanism of prostate cancer chemoresistance and practical assay design.
-
Fluorouracil: From DNA Stress to Tumor Cell State
2026-09-10
Fluorouracil and 5-Fluorouracil are more than cytotoxicity benchmarks: they are tools for connecting thymidylate synthase inhibition with tumor-cell state. This article interprets A4071 data alongside gastric cancer stem-cell biology to improve assay design and mechanistic conclusions.
-
SMC2 and SMC4 Prognostic Markers in Breast Cancer
2026-09-09
A 2024 study integrated transcriptomic, epigenetic, survival, immune, drug-response, and experimental data to identify SMC2 and SMC4 as independent prognostic markers in breast cancer. Its results connect elevated SMC expression with adverse outcomes and show that SMC2 or SMC4 interference increases 5-Fluorouracil and oxaliplatin sensitivity in MCF7 cells, while SMC2 suppression limits xenograft growth.
-
Brefeldin A for Reliable ER–Golgi Assays
2026-09-09
A scenario-driven guide to using Brefeldin A for interpreting viability, proliferation, trafficking, and apoptosis experiments. It explains how SKU B1400 supports controlled ER stress studies through documented concentration, solvent, storage, and incubation parameters.
-
FAISL, Calpain 2, and FAK in TNBC Metastasis
2026-09-08
The reference study identifies FAISL as a focal adhesion kinase-interacting lncRNA that stabilizes FAK by blocking calpain 2-mediated proteolysis. Its findings connect RNA regulation with focal adhesion turnover, TNBC cell plasticity, and metastatic progression, while suggesting experimental routes for studying protease-dependent FAK cleavage.